Enterprise Value to EBITDA Ratio: Advanced Biomed Corp (ADVB)
Advanced Biomed Inc (ADVB) generates revenue through the implementation of tumor marker detection systems that enable rapid adjustments to therapy regimens. Automated microfluidic devices replace manual laboratory labor, representing state-of-the-art robotics. The project is currently focused on R&D to create affordable tumor screening. The EV/EBITDA ratio stands at 0.00, which is clearly reflected in the company's price chart.
Metric breakdowns and analytics for advanbiomed.com (ADVB)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
ADVB - Company Profit|Projected Future Earnings Advanced Biomed Inc|ADVB - Price to Earnings Ratio|Forward P/E Multiple Advanced Biomed|ADVB - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple ADVB|ADVB - Operating profit before amortization|Net earnings per share for the last 12 months Advanced Biomed|ADVB - Earnings per share for the trailing year|Quarterly EPS earnings growth advanbiomed.com|ADVB - Earnings per share growth in current year|Earnings growth forecast for next year Advanced Biomed Inc
Fundamental company valuation:Advanced Biomed Corp (ADVB)
For Advanced Biomed Inc (ADVB), which is developing high-tech AI-based cancer screening, the company's EV/EBITDA multiple allows for a correlation between the total enterprise value, including debt load, and its operating profit before taxes and amortization. The trend of this metric helps investors determine the degree of asset overvaluation and assess the company's financial stability amidst its expansion into the global diagnostics market.
Who Advanced Biomed Inc competes with
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|EV/EBITDA Multiple delcath.com (DCTH)|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|AURA: Enterprise Value to Operating Income Before Depreciation|CADL: Enterprise Value to EBITDA Ratio|ARAY: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLS: EV/EBITDA Multiple|actuatetherapeutics.com (ACTU) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|Enterprise Value to Operating Income Before Depreciation HURA (TuHURA)|EV/EBITDA Multiple TARA|Enterprise Value to EBITDA Ratio Fate Pharma FATE|EV/EBITDA Multiple WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Company Value to EBITDA|Champions Oncology Corp - EV/EBITDA Multiple|XBIT (XBiotech Inc.) - Enterprise Value to Operating Income Before Depreciation|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OS Therapies, Inc. - Business Value to Operating Income Before Depreciation|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ARTV|EV/EBITDA Multiple ANL|Total Company Value to Operating Income Before Depreciation Ratio Veru Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|Xilio Therapeutics Inc (XLO) - Company Value to EBITDA|RENB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Mural Oncology plc (MURA) - Enterprise Value to EBITDA Ratio|KAPA: EV/EBITDA Multiple|Company Value to EBITDA OnKure Therapeutics (OKUR)|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CRIS (Curis Corp)|Enterprise Value to EBITDA Ratio APLM (Apollomics, Inc.)|THAR (tharimmune.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIO (Xenetic Biosciences) - Enterprise Value to Operating Income Before Depreciation|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple BeiGene Ltd.|EV/EBITDA Multiple CKPT|Elevation Oncology Inc. - Enterprise Value to Operating Income Before Depreciation|iCAD - Enterprise Value to EBITDA Ratio|Ikena Oncology Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Notable Labs - EV/EBITDA Multiple|VIRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MOR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NAYA Biosciences Corp|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
